Investment Summary |
|
|---|---|
| Date | 2018-01-01 |
| Target | Marker Therapeutics |
| Sector | Life Science |
| Investor(s) | Aisling Capital |
| Deal Type | PIPE |
SEARCH BY
| Category | Private Equity Firm |
|---|---|
| Founded | 2000 |
| PE ASSETS | 1.8B USD |
| Size | Large |
| Type | Sector Focused |
Aisling Capital is a private investment firm focused on opportunities in the healthcare and medical technology sectors. The Firm specifically looks to invest in companies developing and commercializing innovative healthcare products, services, and technologies. Aisling Capital looks to commit $20 to $50 million per investment and prefers to be the lead investor. Aisling will consider investing in both public and private companies. Aisling Capital raised its first fund in 2000. The Firm is based in New York City.
| DEAL STATS | # |
|---|---|
| Overall | 47 of 56 |
| Sector: Life Science M&A | 36 of 42 |
| Type: PIPE M&A Deals | 10 of 12 |
| State: Texas M&A | 1 of 1 |
| Country: United States M&A | 44 of 52 |
| Year: 2018 M&A | 7 of 7 |
| DATE | TARGET | DEAL TYPE | VALUE |
|---|---|---|---|
| 2018-01-01 |
Spyre Therapeutics
Waltham, Massachusetts, United States Spyre Therapeutics is a biopharmaceutical company developing human enzyme therapeutics for rare genetic diseases invented in the laboratory of George Georgiou, Ph.D. of The University of Texas at Austin. Spyre Therapeutics was incorporated in 2013 and is based in Waltham, Massachusetts. |
Buy | - |
| DATE | TARGET | DEAL TYPE | VALUE |
|---|---|---|---|
| 2018-03-15 |
Arcus Biosciences
Hayward, California, United States Arcus Biosciences is a biotechnology company developing cancer immunotherapies targeting the adenosine and other oncology pathways. Arcus Biosciences was founded in 2015 and is based in Hayward, California. |
Sell | - |
